| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by LCR.
Page 7: 1 2 3 4 5 6 7
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 1801 | 0 | 0 | 1376 2002 BLOOD 100(11):403A-403A Hussein MA; Elson P; Tsoe EA; Karam M; Srkaloci G Doxil (D), vincristine (V), decadron (D) and thalidomide (T) (DVd-T) for relapsed/refractory multiple myeloma (RMM). | 0 | 5 |
| 1802 | 0 | 0 | 1377 2002 BLOOD 100(11):403A-404A Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer S; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE Single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. | 0 | 0 |
| 1803 | 0 | 0 | 1378 2002 BLOOD 100(11):426B-426B Santos E; Goodman M; Byrnes JJ; Fernandez HF Thalidomide as maintenance therapy in the post-transplantation setting in patients with multiple myeloma. | 0 | 0 |
| 1804 | 0 | 0 | 1379 2002 BLOOD 100(11):434A-434A Ghobrial IM; Kumar S; Porrata LF; Gertz MA; Gastineau DA; Ansell SM; Lacy MQ; Rajkumar VS; Micallef IN; Tefferi A; Dispenzieri A; Inwards D; Litzow MR; Markovic SN Thalidomide does not affect immune reconstitution post-autologous bone marrow transplantation in Multiple Myeloma. | 0 | 0 |
| 1805 | 0 | 0 | 1380 2002 BLOOD 100(11):477B-477B Cottler-Fox M; Barlogie B; Anaissie E; Zangari M; Fassas A; Lee CK; van Rhee F; Thertulien R; Tricot G Determinants of high and low CD 34 yield after CAD as part of Total Therapy II (TT II) for newly diagnosed Multiple Myeloma (MM): Effect of Thalidomide (THAL). | 0 | 0 |
| 1806 | 0 | 0 | 1381 2002 BLOOD 100(11):671A-671A LeBlanc R; Hideshima T; Hayashi T; Catley LP; Burger R; Shringarpure R; Cheema P; Richardson P; Anderson KC; Munshi NC Thalidomide analogue IMiD3 provides T cell co-stimulation through B7-CD28 pathway. | 0 | 0 |
| 1807 | 0 | 0 | 1382 2002 BLOOD 100(11):795A-795A Raza A; Lisak LA; Tahir S; Billmeier JM; Willmann HS; Alvi MI; Patkar S; Khan T; Rizvi A; Venugopal P; Gezer S; Mundle SD; Reddy PL Trilineage responses to arsenic trioxide (Trisenox (R)) and thalidomide in patients with myelodysplastic syndromes (MDS), particularly those with inv(3)(q21q26.2). | 0 | 0 |
| 1808 | 0 | 0 | 1383 2002 BLOOD 100(11):800A-800A Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A Thalidomide in Myelofibrosis with Myeloid Metaplasia: A pooled-analysis of individual patient data from five studies. | 0 | 0 |
| 1809 | 0 | 0 | 1384 2002 BLOOD 100(11):808A-809A Weber D; Albitar M; Delasalle K; Dey A; Rankin K; Gavino M; Walker P; Alexanian R Correlation of peripheral blood plasma levels of angiogenesis factors with treatment of thalidomide (T) or thalidomide-dexamethasone (TD) in prevoiusly untreated patients with multiple myeloma (MM). | 0 | 1 |
| 1810 | 0 | 0 | 1385 2002 BLOOD 100(11):811A-811A Thompson MA; Witzig TE; Timm MM; Haug J; Kumar S; Fonseca R; Greipp PR; Rajkumar SV Angiogenesis and angiogenic cytokines in patients receiving thalidomide for multiple myeloma (MM). | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1811 | 0 | 0 | 1386 2002 BLOOD 100(11):813A-813A Richardson P; Jagannath S; Schlossman R; Alsina M; Desikan RK; Blood E; Weller E; Mitsiades C; Hideshima T; Davies F; Doss D; Freeman A; Bosch J; Patin J; Dalton W; Anderson KC Thalidomide for relapsed multiple myeloma after high dose therapy and stem cell transplantation: Results of an open-label, multicenter phase two study of efficacy, toxicity and correlation with biological activity. | 0 | 0 |
| 1812 | 0 | 0 | 1387 2002 BLOOD 100(11):815A-815A Hayashi T; Hideshima T; Akiyama M; Munshi N; Chauhan D; Anderson KC Mechanisms whereby immunomedulatory analogs of thalidomide augment autologous NK cell anti-myeloma immunity. | 0 | 1 |
| 1813 | 0 | 0 | 1388 2002 BLOOD 100(11):816A-816A Treston AM; Swartz GM; Conner B; Shah J; Pribluda VS Pre-clinical evaluation of a thalidomide analog with activity against multiple myeloma and solid tumors - ENMD-0995 (S-(-)3- (3-amino-phthalimido)-glutarimide). | 0 | 1 |
| 1814 | 0 | 0 | 1391 2002 BONE MARROW TRANSPLANTATION 29:S100-S100 Mohty M; Stoppa A; Blaise D; Isnardon D; Gastaut J; Olive D; Gaugler B Differential regulation of dendritic cell function by the Immunomodulatory drug thalidomide: implications for multiple myeloma therapy | 0 | 0 |
| 1815 | 0 | 0 | 1392 2002 BONE MARROW TRANSPLANTATION 29:S104-S104 Patriarca F; Fill C; Sperotto A; Damiani D; Zaja F; Cerno M; Fanin R Thalidomide overcomes VAD chemoresistance and allows PBSC collection in 3 multiple myeloma patients | 0 | 0 |
| 1816 | 0 | 0 | 1393 2002 BONE MARROW TRANSPLANTATION 29:S255-S256 Dagan L; Ovadia R; Taou D; Bar L The introduction of thalidomide (T) in BMT programs for patients with multiple myeloma (MM): encouraging results and a challenge for nursing team | 0 | 0 |
| 1817 | 0 | 0 | 1395 2002 BRITISH JOURNAL OF CANCER 86:S26-S26 Marriott JB; Clarke IA; Dredge K; Pandha H; Kristaleit H; Polychronis A; Muller GW; Stirling D; Dalgleish AG Thalidomide analogue CDC-501 is safe and well tolerated by patients with end stage cancer and shows evidence of clinical responses and extensive immune activation | 3 | 3 |
| 1818 | 0 | 0 | 1396 2002 BRITISH JOURNAL OF CANCER 86:S42-S42 Braybrooke JP; Madhusudan S; Blann A; Wilner S; Flanagan E; Jenkins A; Echeta C; Perren T; Ganesan TS Randomised phase two study of carboplatin versus carboplatin and thalidomide in patients with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. | 0 | 0 |
| 1819 | 0 | 0 | 1397 2002 BRITISH JOURNAL OF CANCER 86:S117-S118 Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling D; Dalgleish AG A novel subclass of thalidomide analogue with anti-solid tumour activity in which caspase dependent apoptosis is associated with altered expression of BCL-2 family proteins | 0 | 0 |
| 1820 | 0 | 4 | 1405 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(2):576-577 Jones SG; Dolan G; Lengyel K; Myers B Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions | 0 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1821 | 0 | 2 | 1409 2002 BRITISH JOURNAL OF PHARMACOLOGY 137 Paxton JW; Kestell P; Ding Q; Ching LM; Zhou S; Palmer BD; Baguley BC Preliminary investigations into the pharmacokinetic interaction between cyclophosphamide and thalidomide in the mouse | 0 | 0 |
| 1822 | 0 | 0 | 1418 2002 CHEMICAL & ENGINEERING NEWS 80(40):60-60 [Anon] Thalidomide and Frances Kelsey | 0 | 0 |
| 1823 | 0 | 6 | 1427 2002 CLINICAL CANCER RESEARCH 8(8):2751-2751 Neben K Correspondence re: K. Neben et al, High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7 : 2675-2681, 2001. Reply | 0 | 0 |
| 1824 | 0 | 0 | 1430 2002 CLINICAL IMMUNOLOGY 103(3):S95-S95 Verastegui E; Morales R; Martinez R; Barrera J Immunological effects of thalidomide treatment of cancer patients. | 0 | 0 |
| 1825 | 0 | 0 | 1431 2002 CLINICAL PHARMACOLOGY & THERAPEUTICS 71(2):P83-P83 Lakhani N; Gordon S; Figg W; Dionne R Absorption and adverse effects of topical thalidomide. | 0 | 0 |
| 1826 | 0 | 0 | 1438 2002 DRUG METABOLISM REVIEWS 34:148-148 Zhou SF; Li Y; Kestell P; Paxton JW Preliminary study of thalidomide transport by the human intestinal cell line Caco-2 | 0 | 0 |
| 1827 | 0 | 0 | 1441 2002 EUROPEAN JOURNAL OF CANCER 38:S53-S53 Villalona-Calero M; Duan W; Otterson G; Kleiber B; Hindman K; Shah M; Young D; Wu W; Kuhn J Thalidomide modulation of Irinotecan; an NF-kB dependent effect? | 0 | 0 |
| 1828 | 0 | 0 | 1442 2002 EUROPEAN JOURNAL OF CANCER 38:S82-S82 Ng SSW; Kruger EA; Luzzio FA; Eger K; Guetschow M; Hauschildt S; Hecker T; Teubert U; Weiss M; Figg WD In vitro antiangiogenic activity of thalidomide analogues | 0 | 0 |
| 1829 | 0 | 0 | 1447 2002 EXPERIMENTAL HEMATOLOGY 30(6):60-60 Biscardi M; Gavazzi S; Balestri F; Grossi A Angiogenic growth factors (VEGF, TGF-b1, bFGF) and thalidomide effect in myelofibrosis with myeloid metaplasia | 0 | 0 |
| 1830 | 0 | 0 | 1448 2002 EXPERIMENTAL HEMATOLOGY 30(6):98-98 Schey S; Jones R; Raj K; Streetley M A phase I study of an immunomodulatory thalidomide analogue (CC4047) in relapse/refractory multiple myeloma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1831 | 0 | 0 | 1449 2002 EXPERIMENTAL HEMATOLOGY 30(6):98-98 Mohty M; Blaise D; Isnardon D; Olive D; Gaugler B Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide: implications for multiple myeloma therapy | 0 | 0 |
| 1832 | 0 | 0 | 1451 2002 FERTILITY AND STERILITY 77(2):S28-S28 Zhong S; Shen K; Lang J The effects of thalidomide on interleukin-6 and vascular endothelial growth factor expression of endometrial stromal cell in vitro. | 0 | 0 |
| 1833 | 0 | 0 | 1452 2002 FERTILITY AND STERILITY 78(3):S87-S87 Scarpellini F; Sbracia M; Lecchini S; Scarpellini L Anti-angiogenesis treatment with thalidomide in endometriosis: A pilot study. | 0 | 1 |
| 1834 | 0 | 0 | 1453 2002 GASTROENTEROLOGY 122(4):A194-A194 Bauditz J; Wedel S; Lochs H Thalidomide for treatment of intestinal bleeding: Correlation to VEGF | 1 | 1 |
| 1835 | 0 | 0 | 1454 2002 GASTROENTEROLOGY 122(4):A395-A395 Kim JW; Kim SG; Kim HD; Kim CG; Kim BG; Kim JS; Jung HC; Song IS Effect of DA-6034 and thalidomide on trinitrobenzene sulfonic acid-induced murine ileitis | 0 | 0 |
| 1836 | 0 | 0 | 1455 2002 GASTROENTEROLOGY 122(4):A498-A498 Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease | 0 | 0 |
| 1837 | 0 | 0 | 1457 2002 GUT 50:A4-A4 Khan ZH; Simpson E; Cole AT; Macdonald I; Pye D; Austin A; Freeman JG Oesophageal cancer and cachexia: The effects of thalidomide on weight loss and lean body mass in a sequential (metabolic) study | 1 | 1 |
| 1838 | 0 | 0 | 1469 2002 INTERNATIONAL JOURNAL OF CANCER :104-104 Hatjiharissi E; Gerotziafas G; Papaioannou M; Bakaloudi V; Tokmaktsis A; Kaloutsi V; Christakis J; Zervas K Efficacy and tolerability of combination thalidomide-dexamethasone in multiple myeloma patients with refractory disease | 0 | 0 |
| 1839 | 0 | 0 | 1470 2002 INTERNATIONAL JOURNAL OF CANCER :336-337 Chen LT; Chao Y; Yao TJ; Huang JD; Chang JY; Chin YH; Chuang TR; Reed E; Whang-Peng J; Liu TW Phase I and pharmacokinetic studies of oral thalidomide in advanced hepatocellular carcinoma | 0 | 0 |
| 1840 | 0 | 0 | 1471 2002 INTERNATIONAL JOURNAL OF CANCER :402-402 Hatjiharissi E; Gerotziafas G; Hatjileontis C; Galaktidou G; Bakaloudi V; Papaioannou M; Kaloutsi V; Kortsaris A; Christakis J; Zervas K Study of neoangiogenesis and cytokine serum levels in patients with refractory multiple myeloma treated with thalidomide-dexamethasone | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1841 | 0 | 0 | 1497 2002 JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(1):212-212 Heere-Ress E; Boehm J; Hoeller C; Thallinger C; Wolff K; Pehamberger H; Jansen B Anti-tumor effect of thalidomide and dacarbazine in melanoma SCID mouse model | 0 | 0 |
| 1842 | 0 | 0 | 1501 2002 JOURNAL OF NUCLEAR MEDICINE 43(5):267P-267P Kinuya S; Yokoyama K; Li XF; Bai J; Michigishi T; Tonami N Radioimmunotherapy with I-131-monoclonal antibody and antiangiogenic therapy with thalidomide in colon cancer xenografts. | 0 | 0 |
| 1843 | 0 | 0 | 1508 2002 JOURNAL OF PSYCHOPHYSIOLOGY 16(4):249-250 Stoeckel MC; Pollock B; Stoerig P; Witte OW; Schnitzler A; Seitz RJ Mislocalizations across toes as evidence for sensorimotor plasticity in thalidomide embryopathy | 0 | 0 |
| 1844 | 0 | 0 | 1511 2002 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 13:641A-641A Don BR; Vu JT; Eriksson T; Scheffler M; Kaysen GA Thalidomide is rapidly metabolized in hemodialysis patients and has a 3-fold increase in clearance during dialysis. | 0 | 0 |
| 1845 | 0 | 0 | 1512 2002 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 13:733A-734A Yudis M; Sirota RA; Stein HD; Snipes ER; Gronich JH; Ghantous VE; Collins DM Renal failure (RF) in multiple myeloma (MM) - Possible association with pamidronate and thalidomide. | 0 | 0 |
| 1846 | 0 | 1 | 1514 2002 JOURNAL OF THE HISTORY OF BIOLOGY 35(2):387-389 Keiner C Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
| 1847 | 0 | 0 | 1515 2002 JOURNAL OF THE NATIONAL CANCER INSTITUTE 94(17):1270-1272 Friedrich MJ Despite checkered past, thalidomide and its analogues show potential | 0 | 0 |
| 1848 | 0 | 0 | 1516 2002 LANCET ONCOLOGY 3(12):711-711 Lindsey H Thalidomide plus dexamethasone for newly diagnosed myeloma | 0 | 0 |
| 1849 | 0 | 0 | 1533 2002 NEUROBIOLOGY OF AGING 23(1):S93-S93 Burke W; Bohac D; Cotter R; Zheng JL; Potter J; Gendelman H A 26 week double blind, placebo-controlled study of the efficacy of thalidomide in the treatment of Alzheimer's disease | 0 | 0 |
| 1850 | 0 | 0 | 1547 2002 PHARMACOTHERAPY 22(10):1362-1362 Ando Y; Price DK; Dahut WL; Cox MC; Reed E; Figg WD Pharmacogenetics of thalidomide: drug response, in vivo metabolism and genetic polymorphism of CYP2C19. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1851 | 0 | 83 | 1552 2002 SOCIAL HISTORY OF MEDICINE 15(1):137-158 Daemmrich A A tale of two experts: Thalidomide and political engagement in the United States and West Germany | 0 | 0 |
| 1852 | 0 | 0 | 1556 2003 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 225:U196-U197 Hu ZG; Pandit B; Shi JD; Zink J; Sackett DL; Li PK Thalidomide analogs with antiproliferative and antimicrotubule activities. | 0 | 0 |
| 1853 | 0 | 0 | 1557 2003 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 225:U197-U197 Luzzio FA; Ng SSW; Gutschow M; Hauschildt S; Weiss M; Teubert U; Kruger E; Mayorov AV; Eger K; Figg WD Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogs. | 0 | 0 |
| 1854 | 0 | 0 | 1568 2003 AMERICAN JOURNAL OF HUMAN GENETICS 73(5):197-197 Kohlhase J; Schubert L; Liebers M; Hennekam RCM; Rauch A; Becker K; Mohammed SN; Wright M; Hannibal MC; Newbury-Ecob R; Reardon W SALL4 mutations result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt-Oram syndrome, Acro-Reno-Ocular syndrome and patients previously reported to represent Thalidomide Embryopathy. | 0 | 0 |
| 1855 | 0 | 0 | 1569 2003 AMERICAN JOURNAL OF HUMAN GENETICS 73(5):286-286 Pan P; Omlin K; Rosenthal J; Padilla O; Stadecker M; Demmer L A case of Restrictive Dermopathy with survival beyond the neonatal period and novel experience with thalidomide therapy | 0 | 0 |
| 1856 | 0 | 4 | 1592 2003 ARCHIVOS DE BRONCONEUMOLOGIA 39(5):240-240 Garcia BD; Gafas AD; Alvarez MJF Lung toxicity due to thalidomide | 0 | 0 |
| 1857 | 0 | 0 | 1594 2003 ARTHRITIS AND RHEUMATISM 48(9):S92-S92 Schechter SJ; Sundel R; Oliveira SK; Huttenlocher A; Onel K; Lehman TJA Thalidomide for severe systemic onset JIA. | 0 | 0 |
| 1858 | 0 | 0 | 1595 2003 ARTHRITIS AND RHEUMATISM 48(9):S587-S587 Doria A; Briani C; Zara G; Rondinone R; Ermani M; Della Libera S; Ghirardello A; Zampieri S; Tedesco S Prospective study on thalidomide-induced peripheral neuropathy in SLE. | 0 | 0 |
| 1859 | 0 | 0 | 1596 2003 ARTHRITIS AND RHEUMATISM 48(9):S588-S589 Vazquez-Cobian LB; Onel KB; Lehman TJA Thalidomide in systemic lupus erythematosus. | 0 | 0 |
| 1860 | 0 | 0 | 1597 2003 ARTHRITIS AND RHEUMATISM 48(9):S617-S617 Efthimiou P; Rosenkranz ME; Mackenzie R; Adler R; Paget SA IVIG and thalidomide combination is an effective novel therapy for scleromyxedema. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1861 | 0 | 0 | 1598 2003 ATHEROSCLEROSIS SUPPLEMENTS 4(2):28-28 Park SJ Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery | 0 | 0 |
| 1862 | 0 | 0 | 1599 2003 BIOFUTUR (238):42-43 Knoll M The return of thalidomide | 0 | 0 |
| 1863 | 0 | 0 | 1601 2003 BIOTECHNOLOGY LAW REPORT 22(2):120-120 [Anon] Celgene, EntreMed agree to license for thalidomide analog - Companies will drop their infringement suits | 0 | 0 |
| 1864 | 0 | 4 | 1603 2003 BLOOD 102(1):2-3 Hussein MA Thalidomide, age, and future use in multiple myeloma | 0 | 0 |
| 1865 | 0 | 0 | 1605 2003 BLOOD 102(11):33A-33A Mesa RA; Elliott MA; Faoro L; Tefferi A Durable and unmaintained remissions with thalidomide-based drug therapy in myelofibrosis with myeloid metaplasia: Long term outcome analysis of 2 prospective trials. | 0 | 0 |
| 1866 | 0 | 0 | 1606 2003 BLOOD 102(11):56B-56B Ballester G; Ballester O; Daitch L; Kutlar A Response to thalidomide therapy in multicentric Castleman's disease. | 0 | 0 |
| 1867 | 0 | 0 | 1607 2003 BLOOD 102(11):148A-148A Palumbo A; Bertola A; Musto P; Nunzi M; De Stefano V; Callea V; Rotoli B; Petti MC; Caravita T; Lauta VM; Patti C; Bringhen S; Cavallo F; Falco P; Carella AM; Liberati AM; Boccadoro M Oral melphalan, prednisone and thalidomide for newly diagnosed myeloma. | 0 | 1 |
| 1868 | 0 | 0 | 1608 2003 BLOOD 102(11):148A-149A Dimopoulos MA; Anagnostopoulos A; Hamilos G; Zomas A; Efstathiou E; Grigoraki V; Poziopoulos C; Gika D; Xilouri I; Zorzou MP; Anagnostopoulos N Pulsed cyclophosphamide, thalidomide and dexamethasone: Long term follow-up of an oral regimen for previously treated patients with multiple myeloma. | 0 | 0 |
| 1869 | 0 | 0 | 1609 2003 BLOOD 102(11):149B-149B Moutouh-de Parseval LA; Glezer E; Corral L; Muller G; Brady H; Mercurio F; Chan K Immunomodulatory thalidomide analogs modulate hematopoietic stem cells developmental pathway. | 0 | 0 |
| 1870 | 0 | 0 | 1610 2003 BLOOD 102(11):236A-236A Zangari M; Barlogie B; Jacobson J; Rasmussen E; Burns M; Kordsmeier B; Shaughnessy JD; Anaissie EJ; Thertulien R; Fassas A; Lee CK; Schenkein D; Zeldis JB; Tricot G VTD regimen comprising velcade (V) plus thalidomide (T) and added DEX (D) for non-responders to V+T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. | 0 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1871 | 0 | 0 | 1611 2003 BLOOD 102(11):237A-237A Niesvizky R; Pekle K; Lyons L; Pearse RN; Bergsagel PL; Schuster MW; Cho HJ; Leonard JP; Coleman M Dexamethsone alone, or in combination with low-dose thalidomide as induction therapy for advanced multiple myeloma, and the effect of the addition of clarithromycin (Biaxin(TM)) on response rate. interim results of a prospective, sequential, randomized trial. | 0 | 0 |
| 1872 | 0 | 0 | 1612 2003 BLOOD 102(11):237A-237A Agrawal NR; Hussein MA; Elson P; Karam MA; Reed J; Srkalovic G Pegylated Doxorubicin(D), Vineristine(V), reduced frequency Dexamethasone(D) and Thalidomide(T) (DVd-T) in newly diagnosed (Nmm) and relapsed/refractory (Rmm) multiple myeloma patients. | 0 | 0 |
| 1873 | 0 | 0 | 1613 2003 BLOOD 102(11):259B-259B Cooper BW; Koc ON; Lazarus HM; Laughlin MJ; Myerson HJ; Creger RJ Phase II study of fludarabine, carboplatin, topotecan, and thalidomide for patients with acute myelogenous leukemia and advanced myelodysplastic syndromes. | 0 | 0 |
| 1874 | 0 | 0 | 1614 2003 BLOOD 102(11):327B-328B Musto P; Falcone A; Sanpaolo G; Bodenizza C; La Sala A; Carella AM Once-weekly recombinant erythropoietin plus thalidomide for the anemia of low-to-intermediate risk myelodysplastic syndromes. | 0 | 0 |
| 1875 | 0 | 0 | 1615 2003 BLOOD 102(11):330B-330B Leb LV; Becker P; Brettler D; Church AA; Khanani SA; Rooney JJ; Seidler CW; Yang J; Woda B The potentiating effect of low dose thalidomide given in combination with epoetin alfa in patients with myelodysplastic syndrome (MDS) having low International Prognostic Scoring Systems (IPSS). | 0 | 0 |
| 1876 | 0 | 0 | 1616 2003 BLOOD 102(11):353B-353B Chanan-Khan AA; Stein L; David S; Takeshita K; Platt J; Miller K; Fallon A; Czuczman MS; Hawthorn L Thalidomide (T) induced in vivo changes in gene expression profile (GEP) of malignant chronic lymphocytic leukemia (CLL) cells. | 0 | 0 |
| 1877 | 0 | 0 | 1617 2003 BLOOD 102(11):359B-359B Kay N; Geyer S; Yaqoob I; Phyliky R; Kutteh L; Li CY Thalidomide (Td) treatment in chronic lymphocytic leukemia (CLL): A North Central Cancer Treatment Group (NCCTG) study. | 0 | 0 |
| 1878 | 0 | 0 | 1618 2003 BLOOD 102(11):366B-367B Okikawa Y; Sakai A; Kuroda Y; Katayama Y; Takimoto Y; Okita H; Kimura A Analysis of the maturity of myeloma cells (plasma cells) is useful to select effective chemotherapy including thalidomide and to predict the progressive disease. | 0 | 0 |
| 1879 | 0 | 0 | 1619 2003 BLOOD 102(11):378B-378B Agrawal NR; Srkalovic G; Sup S; Hsi ED; Elson P; Hussein MA Impact of pegylated doxorubicin(D), vincristine(V), reduced frequency dexamethasone(D) and thalidomide(T) {DVd-T} on bone marrow microvessel density (MVD) in newly diagnosed multiple myeloma (MM) patients (pts). | 0 | 0 |
| 1880 | 0 | 0 | 1620 2003 BLOOD 102(11):380B-380B Myers B; Russell NH; McMillan AK Use of a novel combination chemotherapy for AL-amyloidosis: Cyclophosphamide, thalidomide and dexamethasone - Serum free light chain (SFLC) and serum amyloid protein P (SAP) scan results. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1881 | 0 | 0 | 1621 2003 BLOOD 102(11):381B-381B Breitkreutz I; Cremer FW; Benner A; Moehler T; Fruehauf S; Herrmann D; Ho AD; Goldschmidt H Peripheral blood stem cell collection after CAD plus G-CSF in multiple myeloma: No influence of previous thalidomide administration. | 0 | 0 |
| 1882 | 0 | 0 | 1622 2003 BLOOD 102(11):381B-381B Offidani M; Marconi M; Corvatta L; Malerba L; Olivieri A; Barulli S; Capelli D; Rupoli S; Leoni P Combination therapy with Caelyx, dexamethasone and thalidomide (CDT) for multiple myeloma (MM): Preliminary results of a phase II-III study. | 0 | 0 |
| 1883 | 0 | 0 | 1623 2003 BLOOD 102(11):382B-382B Musto P; Bodenizza C; Falcone A; Sanpaolo G; Cascavilla N; Melillo L; Dell'Olio M; La Sala A; Mantuano S; Nobile M; Scalzulli PR; Greco MM; Carella AM; Beltrami G; Carella AM Treatment of myeloma patients relapsed after frontline autologous stem cell transplantation with the association of thalidomide, dexamethasone and zoledronate. | 0 | 1 |
| 1884 | 0 | 0 | 1624 2003 BLOOD 102(11):382B-382B Novoselac AV; Reddy S; Ohsumi F; Sherman RE; Samaha S Acute myeloid leukemia in patient with multiple myeloma treated with thalidomide. | 0 | 0 |
| 1885 | 0 | 0 | 1625 2003 BLOOD 102(11):382B-383B Caravita T; Siniscalchi A; Niscola P; Santinelli S; Buccisano F; Montanaro M; De Fabritiis P; Amadori S Low dose thalidomide in combination with dexamethasone and cyclophosphamide for management of relapsed/refractory multiple myeloma. | 0 | 0 |
| 1886 | 0 | 0 | 1626 2003 BLOOD 102(11):383B-383B Guglielmelli T; Capella S; Mattioli G; Guerrasio A; Saglio G Thalidomide at very low dosage may represent an effective therapy in relapsed and refractory multiple myeloma. | 0 | 0 |
| 1887 | 0 | 0 | 1627 2003 BLOOD 102(11):383B-384B Spencer A; Roberts A; Bailey M; Schran H; Lynch K No evidence for an adverse interaction between zoledronic acid and thalidomide: Preliminary safety analysis from the Australasian Leukaemia and Lymphoma Group (ALLG) MM6 myeloma trial. | 0 | 0 |
| 1888 | 0 | 0 | 1628 2003 BLOOD 102(11):385B-385B Di Raimondo F; Pennisi A; Buglio D; Fiumara P; Palumbo GA; Giustolisi R Addition of low dose Cyclophosphamide to the combination of Thalidomide and Dexamethasone in patients with relapsed/refractory multiple myeloma. | 0 | 0 |
| 1889 | 0 | 0 | 1629 2003 BLOOD 102(11):385B-386B Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M Combined thalidomide-dexametasone and zoledronic acid induce a reduction of bone resorption markers in newly diagnosed multiple myeloma patients. | 0 | 0 |
| 1890 | 0 | 0 | 1630 2003 BLOOD 102(11):386B-386B Kyriakou CA; D'Sa SP; Flory A; Hanslip J; Peggs KS; Yong KL Cyclophosphamide, dexamethasone and thalidomide (CDT) is a well tolerated and effective regimen in advanced relapsed/refractory myeloma. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1891 | 0 | 0 | 1631 2003 BLOOD 102(11):387B-387B Kumar S; Witzig TE; Wellik L; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Kyle RA; Gertz MA; Greipp PR; Rajkumar SV Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. | 0 | 0 |
| 1892 | 0 | 0 | 1632 2003 BLOOD 102(11):389B-389B Chanan-Khan AA; Miller K; Srinivasan S; David S; McCarthy P; Alam A; Bernstein ZP; Czuczman MS Velcade (Vel), Doxil (R) (Dox) and low-dose thalidomide (Thal) as salvage therapy for patients (pts) with relapsed/refractory multiple myeloma (MM). | 0 | 0 |
| 1893 | 0 | 0 | 1633 2003 BLOOD 102(11):390B-390B Oyan B; Koc Y; Kars A; Turker A; Tekuzman G; Kansu E Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma. | 0 | 0 |
| 1894 | 0 | 0 | 1634 2003 BLOOD 102(11):443A-443A El-Sherbiny YM; Davies FE; Cook G; Johnson RJ; Cullen MJ; Sah A; Rawstron AC; Richards SJ; Morgan GJ NK cell repertoire in myeloma and the impact of thalidomide. | 0 | 0 |
| 1895 | 0 | 0 | 1635 2003 BLOOD 102(11):448A-448A Cavo M; Zamagni E; Tosi P; Cellini C; de Vivo A; Cangini D; Tonelli M; Testoni N; Grafone T; Tacchetti P; Soverini S; Terragna C; Tura S; Baccarani M Primary therapy with thalidomide and dexamethasone in preparation to autologous transplantation for multiple myeloma. | 0 | 0 |
| 1896 | 0 | 0 | 1636 2003 BLOOD 102(11):449A-449A Patten PE; Ahsan G; Kazmi M; Fields PA; Chick GW; Jones RR; Bradwell AR; Schey SA The early use of the serum free light chain assay in patients with relapsed refractory myeloma receiving treatment with a thalidomide analogue (CC-4047). | 0 | 0 |
| 1897 | 0 | 0 | 1637 2003 BLOOD 102(11):450A-450A Zervas K; Dimopoulos MA; Hatziharisi E; Anagnostopoulos A; Papaioannou M; Mitsouli C; Panagiotidis P; Korantzis L; Tzilianos M; Maniatis A Primary treatment of mutiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): A phase II multicenter study. | 0 | 0 |
| 1898 | 0 | 0 | 1638 2003 BLOOD 102(11):450A-451A Comenzo RL; Hassoun H; Reich L; Klimek V; Kewalramani T; Dhodapkar M; Drake L; Hedvat C; Teruya-Feldstein J; Fleisher M; Filippa DA; Nimer SD Doxorubicin and dexamethasone (AD) followed by thalidomide and dexamethasone (TD) as initial therapy for symptomatic patients with multiple myeloma. | 0 | 0 |
| 1899 | 0 | 0 | 1639 2003 BLOOD 102(11):453A-453A Lacy MQ; Dispenzieri A; Gertz MA; Wilzig TE; Greipp PR; Fonseca R; Lust JA; Kumar S; Zeldenrust S; Kyle RA; Snow D; Hayman SR; Sidor CF; Treston AM; Zeldis JB; Rajkumar SV ENMD-0995 (S 3-APG), a novel thalidomide analogue, has promising clinical activity for patients with relapsed refractory multiple myeloma. Preliminary results of a phase I clinical trial. | 0 | 1 |
| 1900 | 0 | 0 | 1640 2003 BLOOD 102(11):453A-454A Abonour R; Ganjoo K; Fausel C; Yiannoutsos C; Juliar BE; Wood LL; Smith GG; Walker P; Cripe LD A phase II study of oral cyclophosphamide, thalidomide, and prednisone (CTP) for patients with relapsed or refractory multiple myeloma, a Hoosier Oncology Group (HOG) trial: HEM01-21. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1901 | 0 | 0 | 1641 2003 BLOOD 102(11):454A-454A Anagnostopoulos A; Efstathiou E; Hamilos G; Zorzou MP; Kastritis E; Dimopoulos MA Patterns of progression in myeloma patients treated with thalidomide-based regimens: High incidence of extramedullary progression without serologic relapse. | 0 | 0 |
| 1902 | 0 | 0 | 1642 2003 BLOOD 102(11):454A-454A Anaissie EJ; Jacobson J; Fassas AB; Zangari M; Thertulien R; VanRhee F; Talamo G; Tricot G; Wendling C; Davis CK; Hollmig K; Barlogie B Safety of total therapy II with or without thalidomide (THAL) for newly diagnosed myeloma: A study of 475 consecutive patients. | 0 | 0 |
| 1903 | 0 | 0 | 1643 2003 BLOOD 102(11):456B-456B Yakoub-agha I; Mohty M; Attal M; Marit G; Bulabois CE; Sotto JJ; Gratecos N; Rio B; Vernant JP; Dib M; Garban F; Cahn JY; Jouet JP; Facon T Thalidomide (THAL) as salvage therapy for relapsed multiple myeloma (MM) after allogeneic stem cell transplantation (SCT). | 0 | 0 |
| 1904 | 0 | 0 | 1644 2003 BLOOD 102(11):489B-490B Grosskreutz CL; Egan R; Scigliano E; Fruchtman SM; Isola LM Thalidomide maintenance after autologous stem cell transplantation for multiple myeloma. | 0 | 0 |
| 1905 | 0 | 0 | 1645 2003 BLOOD 102(11):490B-490B Castro J; Davila J; Perez S; Flores L; Lopez A; Roman A; Pacheco E; Fernandex A; Fradera J; Garcia R; Merle S; Velez-Garcia E High dose chemotherapy (HDC) with autologous transplant (AT) followed by thalidomide (T) as maintenance in patients (P) with multiple myeloma (MM). | 0 | 0 |
| 1906 | 0 | 0 | 1646 2003 BLOOD 102(11):554A-554A Biemond BJ; Havik SR; Meijers JCM; Levi MM; Van Oers MHJ Strong thrombogenic activity of the combined administration of thalidomide and doxorubicin in experimental thrombosis in the rabbit. | 0 | 0 |
| 1907 | 0 | 0 | 1647 2003 BLOOD 102(11):675A-675A Chanan-Khan AA; Fallon A; Miller K; Bernstein ZP; Hernandez F; Alam A; McCarthy P; Mohr A; Czuczman MS Thalidomide (T) and fludarabine (F) as front-line therapy for patients (pts) with previously untreated chronic lymphocytic leukemia (CLL): Results of a phase I trial. | 0 | 0 |
| 1908 | 0 | 0 | 1648 2003 BLOOD 102(11):684A-684A Badros AZ; Ratterree B; Natt S; Rapoport AP; Zeldis JB; Frankel SR; Meisenberg B; Takebe N; Zwiebel JA; Zhang B; Fenton R Phase I/II trial of oblimersen sodium (G3139), dexamethasone (Dex) and thalidomide (Thal) in patients with relapsed multiple myeloma. | 0 | 1 |
| 1909 | 0 | 0 | 1649 2003 BLOOD 102(11):686A-686A Hovenga S; Daenen SMGJ; de Wolf JTM; van Imhoff GW; Kluin-Nelemans HC; Vellenga E Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma. A prospective phase III study. | 0 | 0 |
| 1910 | 0 | 0 | 1650 2003 BLOOD 102(11):687A-687A Latif T; Elson P; Karam MA; Reed J; Tahir K; Srkalovic G; Hussein MA Incidence of renal impairment (RI) in multiple myeloma (MM) patients receiving combination chemotherapy and thalidomide (Thal) with bisphosphonate therapy. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1911 | 0 | 0 | 1651 2003 BLOOD 102(11):687A-687A Zangari M; Barlogie B; Lee CK; Kang SH; Fassas A; Thertulien R; Van Rhee F; Talamo G; Burns M; Anaissie EJ; Tricot G; Jacobson J Increment in bone phophatase (ALP) in myeloma patients during treatment with velcade, thalidomide and dexamethasome (VTD) is a strong predictor for response. | 0 | 0 |
| 1912 | 0 | 0 | 1652 2003 BLOOD 102(11):689A-689A Hattori Y; Kakimoto T; Okamoto S; Iguchi T; Morita K; Tanigawara Y; Ikeda Y Plasma concentration of thalidomide and clinical efficacy in patients with multiple myeloma. | 0 | 0 |
| 1913 | 0 | 0 | 1653 2003 BLOOD 102(11):691A-691A Feyler S; Jackson G; Rawstron A; El-Sherbiny YM; Snowden JA; Johnson RJ Thalidomide maintenance following high dose therapy in multiple myeloma: A UK myeloma forum phase 2 study. | 0 | 1 |
| 1914 | 0 | 0 | 1654 2003 BLOOD 102(11):691A-692A Hoyer B; Fenk R; Steidl U; Kondakci M; Germing U; Haas R; Kobbe G Single agent thalidomide for treatment of first relapse following high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. | 0 | 0 |
| 1915 | 0 | 0 | 1655 2003 BLOOD 102(11):692A-692A Moehler T; Hillengass J; Gerull S; Benner A; Schlenzka J; Neben K; Egerer G; Schaefer H; Goerner M; He AD Thalidomide (T) and CED chemotherapy followed by stem cell transplantation for poor prognosis multiple myeloma. | 0 | 0 |
| 1916 | 0 | 0 | 1656 2003 BLOOD 102(11):829A-830A Lentzsch S; Koh KR; Stirling D; Zenke M; Dorken B Immunomodulatory derivative of thalidomide (IMiD CC-4047) determine the lineage commitment of hematopoietic progenitors by down regulation of GATA-1 and modulation of cytokine secretion. | 0 | 0 |
| 1917 | 0 | 0 | 1657 2003 BLOOD 102(11):903A-903A Mitsiades CS; Mitsiades N; McMullan CJ; Poulaki V; Shringarpure R; Hideshima T; Chauhan D; Treon SP; Richardson PG; Munshi NC; Joseph M; Libermann TA; Anderson KC Immunomodulatory thalidomide derivatives have activity against tumor cells from Waldenstrom's macroglobulinemia. | 0 | 0 |
| 1918 | 0 | 0 | 1658 2003 BLOOD 102(11):923A-924A Elliott MA; Geyer SM; Camoriano JK; Kahanic SP; Alexander SJ; Medgyesy DC; Li CY; Tefferi A Low dose thalidomide (Td) treatment in myelofibrosis with myeloid metaplasia (MMM): An NCCTG study. | 0 | 0 |
| 1919 | 0 | 0 | 1659 2003 BLOOD 102(11):938A-938A Anagnostopoulos A; Zervas K; Zomas A; Pouli A; Hamilos G; Anagnostopoulos N; Dimopoulos MA The International Prognostic Index (IPI) is predictive for survival in refractory or relapsed myeloma patients treated with thalidomide-based regimens. | 0 | 0 |
| 1920 | 0 | 0 | 1660 2003 BLOOD 102(11):984A-984A Sahebi F; Somlo G; Kogut NM; Falk PM; Spielberger R; Parker PM; Krishnan A; Frankel P; Kosobayashi N; Forman SJ Feasibility and toxicity of maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1921 | 0 | 0 | 1661 2003 BLOOD 102(11):985A-986A Somlo G; Yamamoto N; Carter N; O'Donnell M; Snyder D; Sahebi F; Krishnan A; Fung H; Stein A; Spielberger R; Schriber J; Alvarnas J; Chow W; Nademance A; Jasmine Z; Stephen F High complete response rate is associated with improved progression-free and overall survival in 104 patients with multiple myeloma, treated with tandem cycle high-dose melphalan and busulfan/cytoxan, and maintenance interferon alpha-2 (IF) with, or without thalidomide (Thai) | 0 | 0 |
| 1922 | 0 | 0 | 1662 2003 BONE MARROW TRANSPLANTATION 31:S76-S77 Tueger S; Chen F; Ahsan G; Andrews V; Kazmi M; Madrigal J; Schey S Thalidomide-induced remission of refractory diffuse large B-cell lymphoma post-allogeneic SCT - a result of modulation of CTL function? | 0 | 0 |
| 1923 | 0 | 0 | 1663 2003 BONE MARROW TRANSPLANTATION 31:S78-S79 Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fili C; Cerno M; Fanin R Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients | 0 | 0 |
| 1924 | 0 | 1 | 1665 2003 BONE MARROW TRANSPLANTATION 31(11):1067-1067 Alam AR Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT - Reply to the letter by V Pitini | 0 | 0 |
| 1925 | 0 | 0 | 1669 2003 BRITISH JOURNAL OF CANCER 88:S28-S28 Dalgleish A; Schey S; Jones R; Raj K; Dredge K; Streetly M; Marriott B Thalidomide analogues CC-5013 and CC-4047 induce T cell activation and IL-12 production in patients with both solid tumours and relapsed and refractory multiple myeloma. | 0 | 0 |
| 1926 | 0 | 0 | 1670 2003 BRITISH JOURNAL OF CANCER 88:S46-S46 Malpas J; Chaplin T; Sanmugathasan A; Liu W In vitro activity of S-thalidomide against multiple myeloma cells: A gene and protein expression profile. | 0 | 0 |
| 1927 | 0 | 0 | 1674 2003 BRITISH JOURNAL OF DERMATOLOGY 149:81-81 Strauss RM; Bate J; Clayton T; Gooi J; Darling J; Newton-Bishop JA A child with laryngo-onycho-cutaneous syndrome successfully treated with thalidomide | 0 | 0 |
| 1928 | 0 | 3 | 1687 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(4):748-748 Luminari S; Federico M; Baldini L Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide - Response to Mileshkin et al. | 0 | 0 |
| 1929 | 0 | 1 | 1688 2003 BRITISH MEDICAL JOURNAL 327(7418):767-767 Burgermeister J Head of German medicines body likens HRT to thalidomide | 0 | 0 |
| 1930 | 0 | 0 | 1691 2003 CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 12(11):1288S-1288S Hsu C; Chen HN; Chen LT; Wu CY; Hsieh FJ; Cheng AL Use of power Doppler sonography and circulating angiogenic factors to assess the potential antiangiogenic effect of thalidomide in hepatocellular carcinoma. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1931 | 0 | 0 | 1696 2003 CIRCULATION 108(17):170-170 Kirchmair R; Murayama T; Rittig K; Tietz A; Walter D; Schratzberger P; Weinberg DH; Ropper AH; Isner JM Therapeutic angiogenesis inhibits and rescues chemotherapy induced peripheral neuropathy: Taxol, cisplatin and thalidomide induced injury vasa nervorum is ameliorated by VEGF gene therapy | 0 | 0 |
| 1932 | 0 | 0 | 1699 2003 CLINICAL CANCER RESEARCH 9(14):5429-5429 Ching LM; Baguley BC; Kestell P; Palmer BD; Lu J Correspondence re: J. Lu et al., Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9 : 1680-1688, 2003. - Reply | 0 | 0 |
| 1933 | 0 | 0 | 1701 2003 CLINICAL CANCER RESEARCH 9(16):6150S-6150S Baas P; Haringhuizen A; Boogerd W; Dalesio O; Van Zandwijk N Thalidomide in malignant pleural mesothelioma: Results of a phase II study. | 0 | 0 |
| 1934 | 0 | 0 | 1705 2003 CLINICAL PHARMACOLOGY & THERAPEUTICS 73(2):P55-P55 Gordon SM; Wahl SM; Picco C; Dionne RA Safety and tolerability and absorption of topical thalidomide. | 0 | 0 |
| 1935 | 0 | 0 | 1715 2003 DRUG METABOLISM AND DISPOSITION 31(8):1072-1072 Miyata M CYP1A1-mediated activation of thalidomide and suppression of embryo fibroblast proliferation - Reply | 0 | 0 |
| 1936 | 0 | 0 | 1716 2003 EUROPEAN JOURNAL OF CANCER 39(7):854-854 [Anon] Thalidomide on trial | 0 | 0 |
| 1937 | 0 | 0 | 1719 2003 EXPERIMENTAL HEMATOLOGY 31(7):198-198 Moutouh-De Parseval L; Glezer E; Corral L; Galliher A; Wu J; Brady H; Mercurio F; Chan K Immunomodulatory thalidomide analogs modulate hematopoietic stem cell developmental pathways | 0 | 0 |
| 1938 | 0 | 0 | 1721 2003 FASEB JOURNAL 17(7):C124-C124 Dredge K; Marriott JB; Todryk SM; Klaschka D; Horsfall R; Dalgleish A The role of thalidomide-related IMiDs in the induction of innate and adaptive anti-tumor immunity | 0 | 0 |
| 1939 | 0 | 0 | 1722 2003 GASTROENTEROLOGY 124(4):A10-A10 Jin SH; Kim WH; Kim TI; Yang KM; Shin SK; Lee SK; Park SJ; Choi CH; Lee WJ Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR | 0 | 0 |
| 1940 | 0 | 0 | 1723 2003 GASTROENTEROLOGY 124(4):A336-A336 Kim YS; Kim JS; Jung HC; Song IS The effects of thalidomide on NF-R activity and TNF-production stimulated with lipopolysaccharide in a human colonic epithelial cell line ka | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1941 | 0 | 0 | 1724 2003 GASTROENTEROLOGY 124(4):A525-A525 Gupta P; Andrew H; Kirschner BS Thalidomide therapy for pediatric patients with refractory Crohn's disease not responding to infliximab | 0 | 0 |
| 1942 | 0 | 0 | 1738 2003 JOURNAL OF BONE AND MINERAL RESEARCH 18:S310-S310 Bose N; Bergemann H; Westendorf JJ; Rajkumar SV; Masellis AM Expression of alternatively spliced Runx2 in multiple myeloma patients and a shift in expression in response to thalidomide treatment. | 0 | 0 |
| 1943 | 0 | 0 | 1766 2003 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 14:807A-807A Yaqub MS Acute renal failure in multiple myeloma patient receiving thalidomide and zoledronic acid infusion. | 0 | 0 |
| 1944 | 0 | 0 | 1767 2003 JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION 222(3):273-273 [Anon] Veterinary use of thalidomide forbidden by FDA | 0 | 0 |
| 1945 | 0 | 0 | 1771 2003 JOURNAL OF UROLOGY 169(4):233-233 Clark PE; Hall MC; Ridenhour KP; Stindt D; Patton SE; Brinkley W; Das S; Torti FM Phase II trial of thalidomide and interferon-alpha in advanced renal cell carcinoma | 0 | 0 |
| 1946 | 0 | 0 | 1772 2003 LANCET ONCOLOGY 4(2):70-70 Bonn D Thalidomide: no benefit in myelofibrosis with myeloid metaplasia | 0 | 0 |
| 1947 | 0 | 0 | 1773 2003 LANCET ONCOLOGY 4(12):713-713 Habeck M Australia approves thalidomide | 0 | 0 |
| 1948 | 0 | 0 | 1778 2003 LEPROSY REVIEW 74(3):294-295 Naafs B The return of thalidomide: new uses and renewed concerns - reply | 0 | 1 |
| 1949 | 0 | 0 | 1810 2003 PHARMACOPSYCHIATRY 36(5):263-264 Schuld A; Hinze-Selch D; Haack M; Dalal MA; Himmerich H; Lancel M; Pollmacher T Sleep changes following chlorpromazine, clozapine, olanzapine or thalidomide in healthy subjects - First results from a double-blind, placebocontrolled study | 0 | 0 |
| 1950 | 0 | 0 | 1851 2004 BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS 1657:55-56 Gattermann N Sequential dHPLC analysis of a clonally expanded mitochondrial tRNALeu(UUR) mutation (G3242A) in a patient with myelodysplastic syndrome (preleukemia) during successful treatment with thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1951 | 0 | 0 | 1852 2004 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 10(2):73-73 Grosskreutz CL; Egan R; Scigliano E; Fruchtman SM; Isola LM Thalidomide maintenance after autologous stem cell transplantation for multiple myeloma | 0 | 0 |
| 1952 | 0 | 0 | 1858 2004 BONE 34:S97-S97 Spencer A; Roberts A; Bailey M; Schran H; Lynch K Safety and pharmacokinetic analysis of zoledronic acid in a multicentre randomised trial of post-transplant thalidomide maintenance therapy for multiple myeloma | 0 | 0 |
| 1953 | 0 | 0 | 1859 2004 BONE MARROW TRANSPLANTATION 33:S156-S156 Yakoub-Agha I; Mohty M; Attal M; Marit G; Bulabois C; Sotto JJ; Gratecos N; Rio B; Vernant JP; Facon T; Jouet JP; Intergrp Francophne Myelome & SGFM Thalidomide as salvage therapy for relapsed multiple myeloma after allogeneic stem cell transplantation | 0 | 0 |
| 1954 | 0 | 0 | 1860 2004 BONE MARROW TRANSPLANTATION 33:S156-S157 Hardan I; Kneller A; Shimoni A; Berkowicz M; Avigdor A; Yeshurun M; Raanani P; Davidowich Y; Shemtov N; Ben Bassat I; Nagler A Salvage of multiple myeloma patients relapse after an autologous stem cell transplantation, in the era of thalidomide and reduced-intensity allogeneic stem cell transplantation | 0 | 0 |
| 1955 | 0 | 0 | 1861 2004 BONE MARROW TRANSPLANTATION 33:S160-S161 Ciepluch H; Knopinska-Posluszny W; Czyz J; Hellmann A Employment of autologous transplantation of progenitor cells following effective treatment with thalidomide of patients with multiple myeloma resistant to conventional chemotherapy | 0 | 0 |
| 1956 | 0 | 0 | 1862 2004 BONE MARROW TRANSPLANTATION 33:S161-S161 Trojan A; Giger R; Rist N; Jager D; Taverna C Thalidomide stimulates peptide specific CD8+T-cells against viral epitopes | 0 | 0 |
| 1957 | 0 | 0 | 1863 2004 BONE MARROW TRANSPLANTATION 33:S162-S162 Hoyer B; Fenk R; Steidl U; Germing U; Haas R; Kobbe G Treatment of patients with multiple myeloma in first relapse after high-dose chemotherapy with single agent thalidomide - duration of first remission is the major prognostic factor for EFS and OS | 0 | 0 |
| 1958 | 0 | 0 | 1864 2004 BONE MARROW TRANSPLANTATION 33:S165-S165 Offidani M; Marconi M; Corvatta L; Malerba L; Olivieri A; Mele A; Galieni P; Centurioni R; Alesiani F; Candela M; Leoni P Combination thalidomide, doxil and dexamethasone as salvage therapy for patients relapsed after tandem autotransplant | 0 | 0 |
| 1959 | 0 | 0 | 1865 2004 BONE MARROW TRANSPLANTATION 33:S356-S356 Alegre A; Martinez-Chamorro C; Escudero A; Aguado B; Osorio S; Nistal S; Cordoba R; Gil-Fernandez J; Sanchez-Godoy P; Burgaleta C; Casado F; Fernandez-Ranada JM Maintenance treatment with bisphosphonates plus interferon plus dexamethasone plus thalidomide (quadruple maintenance) after autologous peripheral blood stem cell transplantion in multiple myeloma: preliminary results | 0 | 0 |
| 1960 | 0 | 0 | 1868 2004 BRITISH JOURNAL OF CANCER 91:S33-S33 Muthuramalingam SR; Madhusudan S; Vasey PA; Patel P; Christodolus K; Protheroe A; Harris AL A randomised phase II study of interferon-a alone or in combination with thalidomide in metastatic renal cell carcinoma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1961 | 0 | 0 | 1870 2004 BRITISH JOURNAL OF HAEMATOLOGY 125:20-20 Morris TCM; Hull DR; Boyd C; Jones FCG; Kettle PJ; Drake M; McLoughlin R; Quinn J Clarithromycin, dexamethasone and low dose thalidomide (CDT) is effective therapy in relapsed/refractory myeloma and useful in patients with cytopenias | 0 | 0 |
| 1962 | 0 | 0 | 1876 2004 CANADIAN JOURNAL OF GASTROENTEROLOGY 18(6):419-419 Hershfield NB Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18(2): 101-104. Response | 0 | 0 |
| 1963 | 0 | 37 | 1900 2004 EXPERIMENTAL BRAIN RESEARCH 156(3):333-341 Stoeckel MC; Pollok B; Schnitzler A; Witte OW; Seitz RJ Use-dependent cortical plasticity in thalidomide-induced upper extremity dysplasia: evidence from somaesthesia and neuroimaging | 0 | 0 |
| 1964 | 0 | 0 | 1902 2004 FASEB JOURNAL 18(4):A68-A68 Segarra M; Lozano E; Vilardell C; Esparza J; Izco N; Blade J; Campo E; Cid MC Thalidomide (Thd) decreases Fibronectin (FN)-induced gelatinase (MMP-2 and MMP-9) production by B lymphoid cell lines | 0 | 0 |
| 1965 | 0 | 0 | 1904 2004 GASTROENTEROLOGY 126(4):A288-A288 Metz T; Amre D; Jones M; Chen HM; Ouyang W; Haque T; Martoni C; Prakash S Artificial cells containing thalidomide as an alternative oral therapy method for Crohn's disease | 0 | 0 |
| 1966 | 0 | 0 | 1905 2004 GASTROENTEROLOGY 126(4):A396-A397 Gordon JN; Trebble TM; Johns T; Ellis RD; Duncan HD; Goggin PM Thalidomide in the treatment of cancer cachexia: A randomised placebo controlled trial | 0 | 0 |
| 1967 | 0 | 0 | 1906 2004 GASTROENTEROLOGY 126(4):A629-A629 Simon M; Gornet JM; Plane C; Allez M; Colombel JF; Sabate JM; Cortot A; Modigliani R; Lemann M Long term efficacy and toxicity of thalidomide in Crohn's disease | 0 | 0 |
| 1968 | 0 | 1 | 1922 2004 JOURNAL OF CLINICAL ONCOLOGY 22(14):2973-2973 Kumar Thalidomide: Current role in the treatment of non-plasma cell malignancies (vol 22, pg 2477, 20040 | 0 | 0 |
| 1969 | 0 | 0 | 1927 2004 JOURNAL OF INVESTIGATIVE DERMATOLOGY 122(3):A7-A7 Jin JH; Zhang W; Werth VP Thalidomide inhibits the induction of tumor necrosis factor-alpha by ultraviolet B irradiation of human keratinocytes | 0 | 0 |
| 1970 | 0 | 0 | 1928 2004 JOURNAL OF INVESTIGATIVE DERMATOLOGY 123(2) Heere-Ress E; Boehm J; Hoeller C; Wacheck V; Thallinger C; Wolff K; Jansen B; Pehamberger H Thalidomide combined with dacarbazine enhances the anti-tumor activity in a human melanoma xenotransplantation model | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1971 | 0 | 0 | 1929 2004 JOURNAL OF INVESTIGATIVE MEDICINE 52(2):S403-S403 Segarra M; Lozano E; Vilardell C; Esparza J; Izco N; Blade J; Campo E; Cid MC Thalidomide decreases fibronectin-induced gelatinase (MMP-2 and MMP-9) production by B lymphoid cell lines. | 0 | 0 |
| 1972 | 0 | 0 | 1936 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 50(3):P78-P78 Wu JJ; Pang KR; Hsu S; Tyring SK Thalidomide: A review of new indications | 0 | 0 |
| 1973 | 0 | 0 | 1940 2004 JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION 11(2):275A-275A Dharia SP; Steinkampf MP; Parker CR; Grubbs CJ; Crockett S The impact of thalidomide on ovarian function. | 0 | 0 |
| 1974 | 0 | 2 | 1958 2004 MEDICAL JOURNAL OF AUSTRALIA 180(4):199-200 Crawford CL Licensing thalidomide in Australia | 0 | 0 |
| 1975 | 0 | 3 | 1959 2004 MEDICAL JOURNAL OF AUSTRALIA 180(4):200-200 Tattersall MHN Licensing thalidomide in Australia - Reply | 0 | 0 |